补肺健脾益肾方治疗老年肺脾肾气虚型稳定期慢性阻塞性肺疾病临床研究
|
摘要
目的:观察补肺健脾益肾方治疗肺脾肾气虚型稳定期慢性阻塞性肺疾病(COPD)的临床疗效。方法:将120例稳定期COPD患者随机分为2组各60例,对照组采用常规西药常规治疗,研究组在对照组的基础上加用补肺健脾益肾方口服;疗程均为2月,观察比较2组患者肺功能、BODE指数、外周血T淋巴细胞亚群的情况。结果:总有效率治疗组为95.00%,对照组为76.67%,2组比较,差异有统计学意义(P <0.05)。治疗2月后,2组患者的肺功能指标第1秒用力呼气容积(FEV1)、FEV1/FVC (用力肺活量)与治疗前比较,差异均无统计学意义(P> 0.05);2组间治疗后比较,差异亦无统计学意义(P> 0.05)。治疗2月后,研究组BODE指数、6 min步行距离(6MWT)积分、功能性呼吸困难(MMRC)积分和体质量指数(BMI)积分均明显低于对照组(P <0.05);研究组CD3+、CD4+、CD4+/CD8+明显高于对照组(P <0.05),CD8+明显低于对照组(P <0.05)。结论:西药联合补肺健脾益肾方可有效控制肺脾肾气虚型COPD稳定期患者BODE指数,改善患者的细胞免疫功能。
Objective: To observe the clinical effect of Bufei Jianpi Yishen perscrition for chronic obstructive pulmonary disease(COPD) in stable stage of qi-deficiency of the lung, the spleen and the kidney type in senile. Methods: Divided 120 cases of patients with COPD in stable stage into two groups randomly, 60 cases in each group. The control group received routine western medicine for treatment, while the study group additionally received Bufei Jianpi Yishen perscrition orally based on the treatment of the control group. The treatment lasted for two months in the two groups. Observed and compared the lung function, BODE indexes and the peripheral blood T lymphocyte subsets in the two groups. Results: The total effective rate was 95.00% in the observation group and was 76.67% in the control group, the difference being significant(P <0.05). After treatment of two months, compared with the indexes of lung function before and after treatment in the two groups,there was no significance in the difference(P > 0.05); There was no significant between the two groups after treatment. After treatment of two months, BODE indexes and scores of 6 MWT, MMRC and BMI in the study group were obviously lower than those in the control group(P < 0.05).Values of CD3 ~+,CD4~+ and CD4~+/CD8~+ in the study group were significantly higher than those in the control group(P < 0.05), while value of CD8~+ was significantly lower than that in the control group(P < 0.05). Conclusion : The therapy of western medicine combined with Bufei Jianpi Yishen perscrition can effectively control the BODE indexes of patients with COPD in stable stage of qi-deficiency of the lung, the spleen and the kidney type in senile,and improve the cellular immunity function of patients.
Objective: To observe the clinical effect of Bufei Jianpi Yishen perscrition for chronic obstructive pulmonary disease(COPD) in stable stage of qi-deficiency of the lung, the spleen and the kidney type in senile. Methods: Divided 120 cases of patients with COPD in stable stage into two groups randomly, 60 cases in each group. The control group received routine western medicine for treatment, while the study group additionally received Bufei Jianpi Yishen perscrition orally based on the treatment of the control group. The treatment lasted for two months in the two groups. Observed and compared the lung function, BODE indexes and the peripheral blood T lymphocyte subsets in the two groups. Results: The total effective rate was 95.00% in the observation group and was 76.67% in the control group, the difference being significant(P <0.05). After treatment of two months, compared with the indexes of lung function before and after treatment in the two groups,there was no significance in the difference(P > 0.05); There was no significant between the two groups after treatment. After treatment of two months, BODE indexes and scores of 6 MWT, MMRC and BMI in the study group were obviously lower than those in the control group(P < 0.05).Values of CD3 ~+,CD4~+ and CD4~+/CD8~+ in the study group were significantly higher than those in the control group(P < 0.05), while value of CD8~+ was significantly lower than that in the control group(P < 0.05). Conclusion : The therapy of western medicine combined with Bufei Jianpi Yishen perscrition can effectively control the BODE indexes of patients with COPD in stable stage of qi-deficiency of the lung, the spleen and the kidney type in senile,and improve the cellular immunity function of patients.
引文
[1]Wise RA,Chapman KR,Scirica BM,et al.Long-term evaluation of the effects of aclidinium bromide on major adverse cardiovascular events and COPD exacerbations in patients with moderate to very severe COPD:Rationale and design of the ASCENT COPD study[J].Chronic Obstr Pulm Dis,2018,5(1):5-15.
[2]陈国伟.六君子汤联合西药治疗慢性阻塞性肺疾病稳定期临床研究[J].新中医,2016,48(12):30-31.
[3]朱海,黄昕雯,杨荣源,等.慢性阻塞性肺疾病临床表型与中医证型相关性研究[J].新中医,2016,48(10):56-59.
[4]Niederman MS.Pneumonia complicating COPD:Are corticosteroids a help or a hindrance?[J].Chronic Obstr Pulm Dis,2018,5(1):1-4.
[5]覶oban AM,Aksoy E,Duman D,et al.Does eosinophilia and neutrophil to lymphocyte ratio affect hospital re-admission in cases of COPD exacerbation?[J].Tuberk Toraks,2017,65(4):282-290.
[6]Kim MH,Kim YH,Lee DC.Relationships of serum iron parameters and hemoglobin with forced expiratory volume in 1second in patients with chronic obstructive pulmonary disease[J].Korean J Fam Med,2018,39(2):85-89.
[7]Boer LM,Bischoff EW,Borgijink X,et al.'Exacerbation-free time'to assess the impact of exacerbations in patients with chronic obstructive pulmonary disease(COPD):a prospective observational study[J].NPJ Prim Care Respir Med,2018,28(1):12.
[8]Spe N,Maslonka M,Zhang W,et al.Pattern and adherence to maintenance medication use in medicare beneficiaries with chronic obstructive pulmonary disease:2008-2013[J].Chronic Obstr Pulm Dis,2018,5(1):16-26.
[9]Tong X,Cheng A,Xu H,et al.Aspergillus fumigatus during COPD exacerbation:a pair-matched retrospective study[J].BMC Pulm Med,2018,18(1):55.
[2]陈国伟.六君子汤联合西药治疗慢性阻塞性肺疾病稳定期临床研究[J].新中医,2016,48(12):30-31.
[3]朱海,黄昕雯,杨荣源,等.慢性阻塞性肺疾病临床表型与中医证型相关性研究[J].新中医,2016,48(10):56-59.
[4]Niederman MS.Pneumonia complicating COPD:Are corticosteroids a help or a hindrance?[J].Chronic Obstr Pulm Dis,2018,5(1):1-4.
[5]覶oban AM,Aksoy E,Duman D,et al.Does eosinophilia and neutrophil to lymphocyte ratio affect hospital re-admission in cases of COPD exacerbation?[J].Tuberk Toraks,2017,65(4):282-290.
[6]Kim MH,Kim YH,Lee DC.Relationships of serum iron parameters and hemoglobin with forced expiratory volume in 1second in patients with chronic obstructive pulmonary disease[J].Korean J Fam Med,2018,39(2):85-89.
[7]Boer LM,Bischoff EW,Borgijink X,et al.'Exacerbation-free time'to assess the impact of exacerbations in patients with chronic obstructive pulmonary disease(COPD):a prospective observational study[J].NPJ Prim Care Respir Med,2018,28(1):12.
[8]Spe N,Maslonka M,Zhang W,et al.Pattern and adherence to maintenance medication use in medicare beneficiaries with chronic obstructive pulmonary disease:2008-2013[J].Chronic Obstr Pulm Dis,2018,5(1):16-26.
[9]Tong X,Cheng A,Xu H,et al.Aspergillus fumigatus during COPD exacerbation:a pair-matched retrospective study[J].BMC Pulm Med,2018,18(1):55.